Pharmacogenetics of steady-state metabolism, pharmacokinetics, and adverse effects of voriconazole in healthy participants.

ABSTRACT: Voriconazole, a broad-spectrum antifungal, exhibits significant interpatient variability in efficacy and safety. This study assessed the influence of genetic and nongenetic factors on its steady-state pharmacokinetics and adverse effects. In vitro studies characterized voriconazole metabolism. An ancillary analysis was conducted on data from a completed trial involving 61 healthy participants who received a loading dose of 400 mg twice daily on first day, followed by 200 mg twice daily for 8 days. On the third day of voriconazole treatment, plasma and urine samples were collected over a 12-hour period after dose administration. Multiple trough concentrations, adverse events, and laboratory values were recorded throughout the study. Voriconazole and its metabolites were quantified using liq

SUBMITTER: Wu YP 

PROVIDER: S-EPMC12818346 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature